Gastric Fundal Mucosal Ablation to Support Weight Control After Stopping Semaglutide or Tirzepatide in Adults with Obesity

What this Trial Is About

This research investigates the effects of gastric fundal mucosal ablation GFMA on weight changes in adults with obesity who have previously lost more than 10% of their body weight using GLP-1 medications like semaglutide or tirzepatide and are planning to stop these medications. Obesity is a complex and ongoing condition affecting many people, and while incretin mimetics help with weight loss and related health issues, their benefits tend to fade when the medication is stopped. This study aims to explore whether GFMA can help maintain weight loss after stopping these drugs. Participants will undergo a single endoscopic procedure called GFMA, which uses hybrid argon plasma coagulation to treat the lining of the stomachs fundus. This treatment is designed to reduce hunger by lowering levels of the hunger hormone ghrelin and making the stomach less stretchy, helping control appetite. The procedure will be done after participants have discontinued their GLP-1 therapy. During the study, researchers will monitor participants weight changes over 12 months, focusing on the percentage of total body weight lost from the start. They will also assess quality of life, hunger and appetite levels, eating behavior, and any adverse events at multiple points throughout the year. Participants will have regular evaluations to track body mass index, weight recurrence, and their confidence in managing eating and weight.

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)